Pulmonary Delivery of GLP-1 Receptor Agonists: Enabling Rapid Systemic Exposure Through Inhalation Technologies
- Evaluating the lung as a systemic delivery route for GLP-1 receptor agonists, enabling rapid absorption while bypassing gastrointestinal degradation pathways
- Comparing inhalation platforms including dry powder inhalers (DPI) and soft mist inhalers (SMI) for peptide delivery, with focus on formulation constraints, dose loading, and dispersion performance
- Reviewing publicly available pharmacokinetic insights and challenges in achieving clinically relevant systemic exposure via pulmonary delivery
- Discussing manufacturing and scalability considerations for inhaled peptide products, including opportunities to reduce reliance on cold-chain logistics and injection-based delivery systems